乐动体育投注APP

1921
Volume 102, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

乐动体育投注APPArticle metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0754
2018-10-28
2019-01-16
Loading full text...

乐动体育投注APPFull text loading...

/deliver/fulltext/14761645/102/1/tpmd190754.html?itemId=/content/journals/10.4269/ajtmh.19-0754&mimeType=html&fmt=ahah

References

  1. White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, , 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical medicine and Hygiene (ASTMH). Am J Trop Med Hyg 98: 945966.
  2. Garcia HH, 2014. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 14: 687695.
  3. Moyano LM, 2016. High prevalence of asymptomatic neurocysticercosis in an endemic rural community in Peru. PLoS Negl Trop Dis 10: e0005130.
  4. Del Brutto OH, Arroyo G, Del Brutto VJ, Zambrano M, García HH, , 2017. On the relationship between calcified neurocysticercosis and epilepsy in an endemic village: a large-scale, computed tomography-based population study in rural Ecuador. Epilepsia 58: 19551961.
  5. Fleury A, 2003. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 22: 139145.
  6. Marcin Sierra M, 2017. Extraparenchymal neurocysticercosis: demographic, clinicoradiological, and inflammatory features. PLoS Negl Trop Dis 11: e0005646.
  7. Sotelo J, Marin C, , 1987. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 66: 686689.
  8. Sorvillo FJ, DeGiorgio C, Waterman SH, , 2007. Deaths from cysticercosis, United States. Emerg Infect Dis 13: 230235.
  9. Nash T, O’Connell E, Hammoud D, Wetzler L, Ware J, Mahanty S, , 2020. Natural history of treated subarachnoid racemose neurocysticercosis. Am J Trop Med Hyg 102: 7889.
  10. Osorio R, Carrillo-Mezo R, Romo ML, Toledo A, Matus C, González-Hernández I, Jung H, Fleury A, , 2019. Factors associated with cysticidal treatment response in extraparenchymal neurocysticercosis. J Clin Pharmacol 59: 548556.
  11. Serpa JA, Graviss EA, Kass JS, White AC, , 2011. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 90: 8186.
  12. Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F, , 1984. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310: 10011007.
  13. Escobedo F, Penagos P, Rodriguez J, Sotelo J, , 1987. Albendazole therapy for neurocysticercosis. Arch Intern Med 147: 738741.
  14. Carpio A, Santillán F, León P, Flores C, Hauser WA, , 1995. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 155: 19821988.
  15. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CA, Gonzalez AE, Cysticercosis Working Group in Peru; , 2004. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 350: 249258.
  16. Carpio A, Kelvin E, Bagiella E, Leslie D, Leon P, Andrews H, Hauser W, , 2008. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 79: 10501055.
  17. Zhao BC, 2016. Albendazole and corticosteroids for the treatment of solitary cysticercus granuloma: a network meta-analysis. PLoS Negl Trop Dis 10: e0004418.
  18. Agapejev S, Da Silva MD, Ueda AK, , 1996. Severe forms of neurocysticercosis: treatment with albendazole. Arq Neuropsiquiatr 54: 8293.
  19. Proaño JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I, , 2001. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 345: 879885.
  20. Nash TE, Ware JM, Coyle CM, Mahanty S, , 2019. Etanercept to control inflammation in the treatment of complicated neurocysticercosis. Am J Trop Med Hyg 100: 609616.
  21. Kelley R, Duong DH, Locke GE, , 2002. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 50: 757761 ; discussion 761–762.
  22. Suastegui Roman RA, Soto-Hernandez JL, Sotelo J, , 1996. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 84: 629633.
  23. Proaño JV, Torres-Corzo J, Rodríguez-Della Vecchia R, Guizar-Sahagun G, Rangel-Castilla L, , 2009. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst 25: 14671475.
  24. Fleury A, Garcia E, Hernández M, Carrillo R, Govezensky T, Fragoso G, Sciutto E, Harrison LJ, Parkhouse RM, , 2013. Neurocysticercosis: HP10 antigen detection is useful for the follow-up of the severe patients. PLoS Negl Trop Dis 7: e2096.
  25. O’Connell EM, Harrison S, Dahlstrom E, Nash T, Nutman TB, , 2019. A novel, highly sensitive qPCR assay for the diagnosis of subarachnoid and ventricular neurocysticercosis and for assessing response to treatment. Clin Infect Dis. Available at: http://doi.org/10.1093/cid/ciz541.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0754
Loading
  • Received :30 Sep 2019
  • Accepted :30 Sep 2019
  • Published online :28 Oct 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error